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Research on 1,3,4-oxadiazole skeleton derivatives has at-
tracted sizeable interest because of their assorted biological
activity, including anti-HIV activity, (Taoa et al., 2006), anti-
bacterial (Sahin and Palaska, 2002; Ates et al., 1998;
Kocabalkanli et al., 2001), antifungal, analgesic and anti-
inﬂammatory activities (Palaska et al., 2002; Mishrah et al.,
1995; Maccari et al., 2005; Demirbas, 2005) and, smooth mus-ail.com (P.J. Shirote).
y. Production and hosting by
Saud University.
lseviercle relaxant (Ahulwalia et al., 1989; Dhiman et al., 2001).
Moreover, they are also effective in conjunction with imines
and nitric oxide and display diverse potent physiological ac-
tions (Sad, 1996; Ram, 1988; Misra et al., 1996; Shah et al.,
1998; Amir and Kumar, 2004). With regard to the cardiovas-
cular system, it helps to maintain micro- and macro-vascular
homeostasis through several mechanisms including vasodilata-
tion, inhibition of platelet aggregation, and modulation of
platelet and leukocyte adhesion to the endothelium (Mogilaiah
and Sakram, 2004; Gasco et al., 2004). Based on the fact, it is
envisioned that the attachment of imines to the 1,3,4-oxadiaz-
ole can enhance the pulmonary vein relaxation which may con-
tribute to maintain the homeostasis and in continuation of our
research on synthesis of pharmacological active oxadiazole
and imines, herein we report the synthesis of a novel series
of 5-(pyridyl)-1,3,4-oxadiazole. All the title compounds were
evaluated for goat pulmonary vein relaxation (Chand, 1981;
Chand et al., 1979) using force transducer multichannel phys-
iograph (BIOPAC MP35 SYSTEM). The synthesis route is
outlined in Fig. 1.
NC
ONH2NH
N N
O CH3
Ar
N
C
N
CH3
Ar'
N
C
ON
H
NC
CH3
Ar
N N
O CH3
Ar
N
C
O
CH3
ba
c
PSMB1-PSMB15
2(a-f)1(a-f)
Figure 1 Synthesis route of compounds PSMB1–PSMB15. Key:
(a) acetophenones–methanol; (b) acetic anhydride; (c) aromatic
amines.
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2.1. General
Melting points were determined by open capillary method and
were uncorrected. IR spectra (KBr wafer technique) were re-
corded on a Nicolet Impact-410 FT (Nicolet Instrumentation
Corporation, Madison, WI, USA), 1H NMR spectra were re-
corded in CDCl3 on a Brucker 300 MHz (Brucker Magnetics
AG, Faellanden, Switzerland) using TMS as the internal stan-
dard. Mass spectra were obtained with a HPLC/MS LCQ-
DECA spectrometer. HRMS-FAB was obtained with Mass
Spectrometers JoelSX-102. Elemental analysis was performed
on a Perkin–Elmer model 240C analyzer and the data were
within ±0.4% of the theoretical values. The purity of the com-
pounds was conﬁrmed by TLC on silica gel ‘G’ (60-120 mesh
size) coated glass plates.
2.1.1. Typical procedure for synthesis of (2E)-2-[(Z)-2-
aminovinyl]-N0-[1-(aryl)ethylidene]penta-2,4-dienehydrazide
1(a–f)
A solution of 0.01 mol of isoniazid and an equimolar amount
of appropriate acetophenones were added in 25 ml methanol
with a drop of glacial acetic acid, consecutively; the reaction
mixture was reﬂuxed for about 2 h until the disappearance of
the starting material which was ascertained by TLC. The pre-
cipitate obtained was ﬁltered-off; washed with cold methanol
and was then recrystallized from methanol to give 1(a–f).
Analytical and spectral data was obtained for all the
compounds.
2.1.2. (2E)-2-[(Z)-2-aminovinyl]-N0-[1-(phenyl)ethylidene]
penta-2,4-dienehydrazide 1(a)
Yield 84%; m.p. 187–188 C; IR (KBr) Vmax/cm1: 3280 (N–
H), 3010 (Ar, C–H), 1685 (C‚O), 1589 (C‚C), 1575
(C‚N); 1H NMR (CDCl3) d: 2.37 (s, 3H, CH3), 5.23 (s, 1H,
NH), 7.2–7.62 (m, 5H, aromatic). 7.65–8.43 (m, 4H, pyridinyl).
2.1.3. (2E)-2-[(Z)-2-aminovinyl]-N0-[1-(4-chlorophenyl)-
ethylidene]penta-2,4-dienehydrazide 1(b)
Yield 79%; m.p. 205–206 C; IR (KBr) Vmax/cm1: 3295 (N–
H), 2980 (Ar, C–H), 1684 (C‚O), 1589 (C‚C), 1579(C‚N), 670 (C–Cl); 1H NMR (CDCl3) d: 2.33 (s, 3H, CH3),
5.30 (s, 1H, NH), 6.92–7.42 (m, 4H, aromatic). 7.63–8.45 (m,
4H, pyridinyl).2.1.4. (2E)-2-[(Z)-2-aminovinyl]-N0-[1-(4-bromophenyl)-
ethylidene]penta-2,4-dienehydrazide 1(c)
Yield 86%; m.p. 207–208 C; IR (KBr) Vmax/cm1: 3290 (N–
H), 2985 (Ar, C–H), 1690 (C‚O), 1595 (C‚C), 1576
(C‚N), 430 (C–Br).2.1.5. (2E)-2-[(Z)-2-aminovinyl]-N0-[1-(4-methoxyphenyl)-
ethylidene]penta-2,4-dienehydrazide 1(d)
Yield 76%; m.p. 195–196 C; IR (KBr) Vmax/cm1: 3293 (N–
H), 2988 (Ar, C–H), 1693 (C‚O), 1610 (C‚C), 1587
(C‚N); 1H NMR (CDCl3) d: 3.67 (s, 3H, OCH3), 2.42 (s,
3H, CH3), 5.34 (s, 1H, NH), 7.2–7.42 (m, 4H, aromatic).
7.58–8.33 (m, 4H, pyridinyl).2.1.6. (2E)-2-[(Z)-2-aminovinyl]-N0-[1-(4-nitrophenyl)-
ethylidene]penta-2,4-dienehydrazide 1(e)
Yield 83%; m.p. 209–210 C; IR (KBr) Vmax/cm1: 3320 (N–
H), 2994 (Ar, C–H), 1688 (C‚O), 1609 (C‚C), 1578
(C‚N), 1510 (N‚O); 1H NMR (CDCl3) d: 2.38 (s, 3H,
CH3), 5.28 (s, 1H, NH), 7.34–7.62 (m, 4H, aromatic). 7.52–
8.3 (m, 4H, pyridinyl).2.1.7. (2E)-2-[(Z)-2-aminovinyl]-N0-[1-(3-nitrophenyl)-
ethylidene]penta-2,4-dienehydrazide 1(f)
Yield 80%; m.p. 207–208 C; IR (KBr) Vmax/cm1: 3335 (N–
H), 2998 (Ar, C–H), 1689 (C‚O), 1610 (C‚C), 1588
(C‚N), 1505 (N‚O).2.1.8. Typical procedure for synthesis of 1-acetamido-1-(Aryl)
ethyl(1Z,2E,3Z)-2-(2-imino ethylidene)-N-methylpent-3-
enimidoate 2(a–f)
Amixture of 0.01 mol of the appropriate compound 1(a–f) and
an excess of acetic anhydride was reﬂuxed for 2 h until the
completion of the reaction which was monitored by TLC. Ex-
cess of acetic anhydride was distilled off and the residue was
poured onto crushed ice. The solid thus obtained was ﬁltered;
washed with water and was then recrystallized with aqueous
methanol to obtain 2(a–f). Analytical and spectral data was
obtained for all the compounds.2.1.9. 1-Acetamido-1-(phenyl) ethyl(1Z,2E,3Z)-2-(2-
iminoethylidene)-N-methylpent-3-enimidoate 2(a)
Yield 78%; m.p. 154–155 C; IR (KBr) Vmax/cm1: 2995 (Ar,
C–H), 1695 (C‚O), 1587 (C‚C), 1595 (C‚N, oxadiazolyl),
1586 (C‚N, pyridinyl); 1H NMR (CDCl3) d: 2.32 (s, 3H,
CH3), 2.18 (s, 3H, COCH3), 6.9–7.58 (m, 5H, aromatic).
7.62–8.23 (m, 4H, pyridinyl).2.1.10. 1-Acetamido-1-(4-chlorophenyl) ethyl(1Z,2E,3Z)-2-(2-
iminoethylidene)-N-methylpent-3-enimidoate 2(b)
Yield 87%; m.p. 162–163 C; IR (KBr) Vmax/cm1: 2983 (Ar,
C–H), 1689 (C‚O), 1588 (C‚C), 1592 (C‚N, oxadiazolyl),
157 (C‚N), 655 (C–Cl); 1H NMR (CDCl3) d: 2.31 (s, 3H,
CH3), 2.09 (s, 3H, COCH3), 6.91–7.32 (m, 4H, aromatic).
7.58–8.35 (m, 4H, pyridinyl).
Table 1 Physical properties of PSMB1–PSMB15.
Compound Ar Ar1 Molecular formula Molecular weight Color Yield (%)
PSMB1 C22H20N4O
356.43
Light yellow 68
PSMB2 O2N C22H19N5O3 401.43 Yellow 69
PSMB3 Cl O2N C22H18ClN5O3 435.87 Light brown 72
PSMB4 Br O2N C22H18BrN5O3 480.32 Dark yellow 73
PSMB5 Br MeO C23H21BrN4O2 465.35 Light yellow 65
PSMB6 OMe O2N C23H21N5O4 431.45 Yellowish brown 68
PSMB7 NO2 C22H19N5O3 401.43 Light brown 72
PSMB8 NO2 O2N C22H18N6O5 446.43 Yellow 70
PSMB9 NO2 MeO C23H21N5O4 431.45 Brown 67
PSMB10 NO2 C26H21N5O3 451.49 Yellowish -white 68
PSMB11
NO2
C22H19N5O3 401.43 Light brown 69
PSMB12
NO2
O2N C22H18N6O5 446.43 Dark-yellow 73
PSMB13
NO2
Me C23H21N5O3 415.46 Brown 70
PSMB14
NO2
MeO C23H21N5O4 431.45 Brown 63
PSMB15
NO2
C26H21N5O3 451.49 Yellowish -white 64
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iminoethylidene)-N-methylpent-3-enimidoate 2(c)
Yield 78%; m.p. 175–176 C; IR (KBr) Vmax/cm1: 2984 (Ar,
C–H), 1690 (C‚O), 1586 (C‚C), 1593 (C‚N, oxadiazolyl),
1576 (C‚N), 465 (C–Br).2.1.12. 1-Acetamido-1-(4-methoxyphenyl)ethyl(1Z,2E,3Z)-2-
(2-iminoethylidene)-N-methylpent-3-enimidoate 2(d)
Yield 78%; m.p. 165–166 C; IR (KBr) Vmax/cm1: 2986 (Ar,
C–H), 1698 (C‚O), 1589 (C‚C), 1598 (C‚N, oxadiazolyl),
1587 (C‚N); 1H NMR (CDCl3) d: 3.65 (s, 3H, –OCH3),
416 P.J. Shirote, M.S. Bhatia2.39 (s, 3H, CH3), 2.09 (s, 3H, COCH3), 6.98–7.27 (m, 4H, aro-
matic). 7.38–7.98 (m, 4H, pyridinyl).2.1.13. 1-Acetamido-1-(4-nitrophenyl)ethyl(1Z,2E,3Z)-2-(2-
iminoethylidene)-N-methylpent-3-enimidoate 2(e)
Yield 78%; m.p. 123–124 C; IR (KBr) Vmax/cm1: 2984 (Ar,
C–H), 1689 (C‚O), 1580 (C‚C), 1594 (C‚N, oxadiazolyl),
1578 (C‚N), 1508 (N‚O); 1H NMR (CDCl3) d: 2.32 (s,
3H, CH3), 2.07 (s, 3H, COCH3), 7.44–7.67 (m, 4H, aromatic).
7.72–8.14 (m, 4H, pyridinyl).2.1.14. 1-Acetamido-1-(3-nitrophenyl)ethyl(1Z,2E,3Z)-2-(2-
iminoethylidene)-N-methylpent-3-enimidoate 2(f)
Yield 78%; m.p. 128–129 C; IR (KBr) Vmax/cm1: 2983 (Ar,
C–H), 1688 (C‚O), 1584 (C‚C), 1593 (C‚N, oxadiazolyl),
1575 (C‚N), 1510 (N‚O).2.1.15. General procedure for synthesis of N-{(1Z)-1-[2-
methyl-2-(aryl)-5-pyridin-4-yl-1,3,4-oxadiazol-3(2H)-
yl]ethylidene}-aromatic amines (PSMB1–PSMB15)
A mixture of 0.01 mol of 2(a–f) and an equimolar amount of
appropriate aromatic amines was added to 25 ml ethanol
with a drop of glacial acetic acid, was heated under reﬂux
for 5–6 h. The precipitate obtained was ﬁltered-off; washed
with cold ethanol and recrystallized from ethanol to give
PSMB1–PSMB15. Physical properties are given in Table 1
and Analytical and spectral data were obtained from all the
compounds.2.1.16. N-[(1Z)-1-(2-methyl-2-phenyl-5-pyridin-4-yl-1,3,4-
oxadiazol-3(2H)-yl)ethylidene]aniline (PSMB1)
Yield 68%, m.p. 205–206 C; found: C, 73.85; H, 5.10; N,
15.65. Calc. for C22H20N4O (356.43): C, 74.14; H, 5.66; N,
15.72; IR (KBr) Vmax/cm
1: 2983 (Ar, C–H), 1584 (C‚C),
1593 (C‚N, oxadiazolyl), 1575 (C‚N); 1H NMR (CDCl3)
d: 2.30 (s, 3H, CH3), 2.02 (s, 3H, N‚C–CH3), 7.2–7.38 (m,
10H, aromatic), 7.45–8.10 (m, 4H, pyridinyl); MS (m/z): 357
(M+1), 358 (M+2).2.1.17. N-[(1Z)-1-(2-methyl-2-phenyl-5-pyridin-4-yl-1,3,4-
oxadiazol-3(2H)-yl)ethylidene]-4-nitroaniline (PSMB2)
Yield 69%, m.p. 210–211 C; found: C, 64.83; H, 4.85; N,
16.25. Calc. for C22H19N5O3 (401.43): C, 65.83; H, 4.77; N,
17.45; IR (KBr) Vmax/cm
1: 2985 (Ar, C–H), 1586 (C‚C),
1595 (C‚N, oxadiazolyl), 1510 (N‚O), 1573 (C‚N); 1H
NMR (CDCl3) d:2.31 (s, 3H, CH3), 2.01 (s, 3H, N‚C–
CH3), 7.1–7.23 (m, 9H, aromatic), 7.55–8.12 (m, 4H, pyridi-
nyl); MS (m/z): 402 (M+1), 403 (M+2).
2.1.18. N-{(1Z)-1-[2-(4-chlorophenyl)-2-methyl-5-pyridin-4-
yl-1,3,4-oxadiazol-3(2H)-yl]ethylidene}-4-nitroaniline
(PSMB3)
Yield 72%, m.p. 233–234 C; found: C, 61.55; H, 4.10; N, 9.65.
Calc. for C22H18ClN5O3 (435.87): C, 60.62; H, 4.16; N, 8.13;
IR (KBr) Vmax/cm
1: 2963 (Ar, C–H), 1574 (C‚C), 1599
(C‚N, oxadiazolyl), 1517 (N‚O), 1574 (C‚N); 1H NMR
(CDCl3) d: 2.28 (s, 3H, CH3), 2.03 (s, 3H, N‚C–CH3), 6.9–
7.18 (m, 8H, aromatic). 7.15–8.0 (m, 4H, pyridinyl); MS (m/
z): 437 (M+1), 438 (M+2) (HRMS calcd for C22H18ClN5O3
435.8735, found 435.8741).2.1.19. N-{(1Z)-1-[2-(4-bromophenyl)-2-methyl-5-pyridin-4-
yl-1,3,4-oxadiazol-3(2H)-yl]ethylidene}-4-nitroaniline
(PSMB4)
Yield 73%, m.p. 236–237 C; found:C, 54.85;H, 4.10; N, 14.65.
Calc. for C22H18BrN5O3 (480.32): C, 55.01; H, 3.78; N, 14.58;
IR (KBr) Vmax/cm
1: 2963 (Ar, C–H), 1578 (C‚C), 1597
C‚N, oxadiazolyl), 1516 (N‚O), 1569 (C‚N); 1H NMR
(CDCl3) d: 2.35 (s, 3H, CH3), 2.10 (s, 3H, N‚C–CH3), 7.4–
7.60 (m, 8H, aromatic). 7.65–8.10 (m, 4H, pyridinyl); MS
(m/z): 481 (M+1), 482 (M+2) (HRMS calcd for
C22H18BrN5O3 480.3245, found 480.3250).2.1.20. N-{(1Z)-1-[2-(4-bromophenyl)-2-methyl-5-pyridin-4-
yl-1,3,4-oxadiazol-3(2H)-yl]ethylidene}-4-methoxyaniline
(PSMB5)
Yield 65%, m.p. 208–209 C; found: C, 60.15; H, 4.45; N,
12.55. Calc. for C23H21BrN4O2 (465.35): C, 59.36; H, 4.55;
N, 12.04; IR (KBr) Vmax/cm
1: 3010 (Ar, C–H), 1576
(C‚C), 1591 (C‚N, oxadiazolyl), 1572 (C‚N); 1H NMR
(CDCl3) d: 2.30 (s, 3H, CH3), 2.04 (s, 3H, N‚C–CH3), 3.70
(s, 3H, OCH3), 7.1–7.40 (m, 8H, aromatic). 7.45–7.90 (m,
4H, pyridinyl); MS (m/z): 466 (M+1), 467 (M+2) (HRMS
calcd for C23H21BrN4O2 465.3534, found 465.3539).2.1.21. N-{(1Z)-1-[2-methyl-2-(4-methoxyphenyl)-5-pyridin-
4-yl-1,3,4-oxadiazol-3(2H)-yl]ethylidene}-4-nitroaniline
(PSMB6)
Yield 68%, m.p. 210–211 C; found: C, 63.89; H, 4.95; N,
15.65. Calc. for C23H21N5O4 (431.45): C, 64.03; H, 4.91; N,
16.23; IR (KBr) Vmax/cm
1: 2993 (Ar, C–H), 1586 (C‚C),
1598 (C‚N, oxadiazolyl), 1515 (N‚O), 1569 (C‚N); 1H
NMR (CDCl3) d: 2.32 (s, 3H, CH3), 2.01 (s, 3H, N‚C–
CH3), 3.65 (s, 3H, OCH3), 6.5–7.23 (m, 8H, aromatic). 7.35–
7.98 (m, 4H, pyridinyl); MS (m/z): 432 (M+1), 433 (M+2).2.1.22. N-{(1Z)-1-[2-methyl-2-(4-nitrophenyl)-5-pyridin-4-yl-
1,3,4-oxadiazol-3(2H)-yl]ethylidene}-aniline (PSMB7)
Yield 72%, m.p. 179–180 C; found: C, 64.94; H, 4.76; N,
17.85. Calc. for C22H19N5O3 (401.43): C, 65.83; H, 4.77; N,
17.45; IR (KBr) Vmax/cm
1: 2988 (Ar, C–H), 1579 (C‚C),
1596 (C‚N, oxadiazolyl), 1518 (N‚O), 1577 (C‚N); 1H
NMR (CDCl3) d: 2.29 (s, 3H, CH3), 2.03 (s, 3H, N‚C–
CH3), 7.1–7.23 (m, 9H, aromatic). 7.35–8.12 (m, 4H, pyridi-
nyl); MS (m/z): 402 (M+1), 403 (M+2).2.1.23. N-{(1Z)-1-[2-methyl-2-(4-nitrophenyl)-5-pyridin-4-yl-
1,3,4-oxadiazol-3(2H)-yl]ethylidene}-4-nitroaniline (PSMB8)
Yield 70%, m.p. 194–195 C; found: C, 60.25; H, 4.12; N,
19.15. Calc. for C22H18N6O5 (446.43): C, 59.19; H, 4.06; N,
18.83; IR (KBr) Vmax/cm
1: 2983 (Ar, C–H), 1584 (C‚C),
1593 (C‚N, oxadiazolyl), 1522 (N‚O), 1575 (C‚N); 1H
NMR (CDCl3) d: 2.27 (s, 3H, CH3), 2.1 (s, 3H, N‚C–CH3),
7.4–7.60 (m, 8H, aromatic). 7.66–8.13 (m, 4H, pyridinyl);
MS (m/z) 447 (M+1), 448 (M+2).2.1.24. N-{(1Z)-1-[2-methyl-2-(4-nitrophenyl)-5-pyridin-4-yl-
1,3,4-oxadiazol-3(2H)-yl]ethylidene}-4-methoxyaniline
(PSMB9)
Yield 67%, m.p. 178–179 C; found: C, 63.94; H, 5.04; N,
16.65. Calc. for C23H21N5O4 (431.45): C, 64.03; H, 4.91; N,
Table 2 Pulmonary vein relaxant activity of PSMB1–
PSMB15.
Compounds Diﬀerence in tension
(grams)mean ± SEM
% Relaxation (compared
with standard)
PSMB1 0.04 ± 0.0070 22.2
PSMB2 0.02 ± 0.0031 11.1
PSMB3 0.026 ± 0.004 14.44
PSMB4 0.028 ± 0.0037 15.55
PSMB5 0.042 ± 0.0066 23.33
PSMB6 0.03 ± 0.0031 16.66
PSMB7 0.082 ± 0.0037 45.55
PSMB8 0.082 ± 0.0037 45.55
PSMB9 0.15 ± 0.0037* 83.33*
PSMB10 0.028 ± 0. 0037 15.55
PSMB11 0.038 ± 0.0037 21.11
PSMB12 0.04 ± 0.0070 22.22
PSMB13 0.07 ± 0.0044 38.88
PSMB14 0.05 ± 0.0031 27.77
PSMB15 0.032 ± 0.0058 17.77
* p< 0.01, signiﬁcant, alcohol – control, isosorbide dinitrate-
standard drug.
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1: 2983 (Ar, C–H), 1584 (C‚C),
1593 (C‚N, oxadiazolyl), 1524 (N‚O), 1575 (C‚N); 1H
NMR (CDCl3) d: 2.31 (s, 3H, CH3), 2.04 (s, 3H, N‚C–
CH3), 3.75 (s, 3H, OCH3), 7.2–7.5 (m, 8H, aromatic). 7.6–
7.9 (m, 4H, pyridinyl); MS (m/z): 432 (M+1), 433 (M+2).
2.1.25. N-{(1Z)-1-[2-methyl-2-(4-nitrophenyl)-5-pyridin-4-yl-
1,3,4-oxadiazol-3(2H)-yl]ethylidene}-1-napthylamine
(PSMB10)
Yield 68%, m.p. 172–173 C; found: C, 69.45; H, 4.56; N,
15.75. Calc. for C26H21N5O3 (451.49): C, 69.17; H, 4.69; N,
15.51; IR (KBr) Vmax/cm
1: 2979 (Ar, C–H), 1579 (C‚C),
1590 (C‚N, oxadiazolyl), 1519 (N‚O), 1573 (C‚N); 1H
NMR (CDCl3) d: 2.30 (s, 3H, CH3), 2.02 (s, 3H, N‚C-
CH3), 7.34–7.68 (m, 11H, aromatic), 7.74–8.23 (m, 4H, pyrid-
inyl); MS (m/z): 452 (M+1), 453 (M+2).
2.1.26. N-{(1Z)-1-[2-methyl-2-(3-nitrophenyl)-5-pyridin-4-yl-
1,3,4-oxadiazol-3(2H)-yl]ethylidene}-aniline (PSMB11)
Yield 69%, m.p. 185–186 C; found: C, 64.65; H, 4.67; N,
17.65. Calc. for C22H19N5O3 (401.43): C, 65.83; H, 4.77; N,
17.45; IR (KBr) Vmax/cm
1: 2988 (Ar, C–H), 1578 (C‚C),
1596 (C‚N, oxadiazolyl), 1528 (N‚O), 1578 (C‚N); 1H
NMR (CDCl3) d: 2.31 (s, 3H, CH3), 2.03 (s, 3H, N‚C-
CH3), 7.2–7.38 (m, 9H, aromatic), 7.4–8.2 (m, 4H, pyridinyl);
MS (m/z): 402 (M+1), 403 (M+2).
2.1.27. N-{(1Z)-1-[2-methyl-2-(3-nitrophenyl)-5-pyridin-4-yl-
1,3,4-oxadiazol-3(2H)-yl]ethylidene}-4-nitroaniline
(PSMB12)
Yield 73%, m.p. 199–200 C; found: C, 58.45; H, 4.16; N,
17.85. Calc. for C22H18N6O5 (446.43): C, 59.19; H, 4.06; N,
18.83; IR (KBr) Vmax/cm
1: 3012 (Ar, C–H), 1586 (C‚C),
1598 (C‚N, oxadiazolyl), 1533 (N‚O), 1575 (C‚N); 1H
NMR (CDCl3) d: 2.32 (s, 3H, CH3), 2.01 (s, 3H, N‚C–
CH3), 7.2–7.38 (m, 8H, aromatic), 7.45–8.10 (m, 4H, pyridi-
nyl); MS (m/z): 447 (M+1) 448 (M+2).2.1.28. N-{(1Z)-1-[2-methyl-2-(3-nitrophenyl)-5-pyridin-4-yl-
1,3,4-oxadiazol-3(2H)-yl]ethylidene}-p-toludine (PSMB13)
Yield 70%, m.p. 205–206 C; found: C, 67.09; H, 5.10; N,
16.65. Calc. for C23H21N5O3 (415.46): C, 66.49; H, 5.09; N,
16.86; IR (KBr) Vmax/cm
1: 2987 (Ar, C–H), 1578 (C‚C),
1599 (C‚N, oxadiazolyl), 1575 (C‚N), 1535 (N‚O); 1H
NMR (CDCl3) d: 2.32 (s, 3H, CH3), 2.35 (s, 3H, Ar–CH3),
2.05 (s, 3H, N‚C–CH3), 7.12–7.45 (m, 8H, aromatic).
7.48–7.97 (m, 4H, pyridinyl); MS (m/z): 416 (M+1), 417
(M+2).2.1.29. N-{(1Z)-1-[2-methyl-2-(3-nitrophenyl)-5-pyridin-4-yl-
1,3,4-oxadiazol-3(2H)-yl]ethylidene}-4-methoxyaniline
(PSMB14)
Yield 63%, m.p. 184–185 C; found: C, 63.85; H, 5.10; N,
16.35. Calc. for C23H21N5O4 (431.45): C, 64.03; H, 4.91; N,
16.23; IR (KBr) Vmax/cm
1: 2986 (Ar, C–H), 1583 (C‚C),
1597 (C‚N, oxadiazolyl), 1529 (N‚O), 1576 (C‚N); 1H
NMR (CDCl3) d:2.34 (s, 3H, CH3), 2.04 (s, 3H, N‚C–
CH3), 3.76 (s, 3H, OCH3), 7.3–7.67 (m, 8H, aromatic), 7.7–
8.2 (m, 4H, pyridinyl); MS (m/z): 432 (M+1), 433 (M+2).2.1.30. N-{(1Z)-1-[2-methyl-2-(3-nitrophenyl)-5-pyridin-4-yl-
1,3,4-oxadiazol-3(2H)-yl]ethylidene}-1-napthylamine
(PSMB15)
Yield 64%, m.p. 169–170 C; found: C, 70.85; H, 5.10; N,
15.62. Calc. for C26H21N5O3 (451.49): C, 69.17; H, 4.69; N,
15.51; IR (KBr) Vmax/cm
1: 2989 (Ar, C–H), 1587 (C‚C),
1599 (C‚N, oxadiazolyl), 1517 (N‚O), 1572 (C‚N); 1H
NMR (CDCl3) d: 2.29 (s, 3H, CH3), 2.04 (s, 3H, N‚C–
CH3), 7.37–7.71 (m, 11H, aromatic), 7.74–8.28 (m, 4H, pyrid-
inyl); MS (m/z): 452 (M+1), 453 (M+2).2.2. Pulmonary vein relaxant activity
The synthesized compounds PSMB1–PSMB15 were tested
in vitro for their pulmonary vein relaxant activity. Pulmonary
veins and arteries of adult goat of either sex were brought
from a local slaughterhouse. The Media used to carry the
muscle was ice-cold Krebs–Henseleit solution. These were
cut into spiral strips and were used within 12–24 h. These
strips were mounted in 15 ml isolated organ baths, containing
Krebs–Henseleit solution, mixed with 95% O2 and 5% CO2 at
37 C. The composition of the Krebs–Henseleit solution was
(mmol/l): NaCl (118), KCI (4.70), and CaCI2, 2H2O (2.5),
KH2PO4 (1.2), MgSO4, 7H2O (1.2), NaHCO3 (25.0) and glu-
cose 10.0. The strip was allowed to equilibrate for 2 h under a
resting load of 2 g. Relaxation of muscle strip was recorded
for each drug using force transducer multichannel physiog-
raph (BIOPAC MP35 SYSTEM). The title compounds were
compared with isosorbide dinitrate, a standard drug used
for relaxation. Alcohol was used as control. Signiﬁcance was
calculated by using ANOVA followed by the Dunnet ‘t’ test.
The relaxation activity data for all compounds are given in
Table 2.3. Result and discussion
The various title compounds PSMB1–PSMB15 were synthe-
sized cleanly and in fairly good yields. Their structures were
418 P.J. Shirote, M.S. Bhatiaconﬁrmed by an elemental analysis and spectral data. The IR
spectrum of these compounds showed C‚N str. at around
1575 and 1595 cm1 and alkyl stretching at 3010 cm1. The
compound also exhibited appropriate peaks at the correspond-
ing d (ppm) (see spectral data) in their 1H NMR spectra, thus
conﬁrming their structures. All the synthesized compounds
were screened for their pulmonary vein relaxation activity
using goat pulmonary vein. As seen in Table 2, compound
PSMB9 was found to be the most potent, demonstrating
83.33% relaxation as that of isosorbide dinitrate where as
compound PSMB2 was the least potent, exhibiting 11.1%
relaxation. The results of the relaxant activity indicate that
the presence of parasubstituted aryl ring, with electron with-
drawing groups such as 4-nitrophenyl, at C2 atom of oxadiaz-
ole, along with the moderate electron donating substituent at
N3 position appear to be essential for pulmonary vein
relaxation.Acknowledgments
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